NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Unconfirmed

**Date:** Thursday 17 June 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Gary McVeigh (Chair) Present for all items
2. Dr Lindsay Smith (Vice Chair) Present for all items
3. James Avery Present for all items
4. Martin Bradley Present for items 1 to 4.2.2
5. Dr Matt Bradley Present for items 5 to 6.2.2
6. Professor Sofia Dias Present for all items
7. Professor Rachel Elliott Present for items 5 to 6.2.2
8. Rebecca Harmston Present for all items
9. Chris Herring Present for items 6 to 6.2.2
10. Dr Robert Hodgson Present for all items
11. Dr Bernard Khoo Present for all items
12. Dr Soo Fon Lim Present for all items
13. Professor David Meads Present for items 1 to 4.2.2
14. Giles Monnickendam Present for all items
15. Malcolm Oswald Present for all items
16. Dr Rebecca Payne Present for all items
17. Professor Chris Parker Present for all items
18. Professor John Watkins Present for all items

NICE staff present

Jasdeep Hayre, Associate Director Present for items 1 to 4.2.2

Linda Landells, Associate Director Present for items 5 to 5.2.2

Ross Dent, Associate Director Present for items 6 to 6.2.2

Louise Jafferally, Project Manager Present for items 1 to 4.2.2 & 6 to 6.2.2

Kate Moore, Project Manager Present for items 1 to 4.1.3 & 5 to 6.2.2

Victoria Kelly, Health Technology Assessment Adviser Present for items 1 to 4.2.2

Hannah Nicholas, Health Technology Assessment Adviser Present for items 5 to 5.2.2

Sally Doss, Health Technology Assessment Adviser Present for items 6 to 6.2.2

Luke Cowie, Health Technology Assessment Analyst Present for items 1 to 4.2.2

Nigel Gumbleton, Health Technology Assessment Analyst Present for items 5 to 5.2.2

Victoria Gillis-Elliott, Health Technology Assessment Analyst Present for items 6 to 6.2.2

Vera Unwin, Health Technology Analyst, DAP Present for items 1 to 4.2.2 & 6 to 6.2.2

Nicola Bodey, Business Analyst, RIA Present for all items

Hayley Garnett, Senior Medical Editor Present for items 1 to 4.2.2

Ria Skelton, Senior Medical Editor Present for items 5 to 5.2.2

Sarah Bromley, Senior Medical Editor Present for items 6 to 6.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Present for all items

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Present for items 1 to 5.2.2

Stevie Okoro, Technical Analyst, Commercial Risk Assessment Present for items 5 to 6.2.2

Laura Marsden, Public Involvement Adviser, PIP Present for items 1 to 4.1.3

Catherine Pank, Assistant Project Manager, COT Present for items 6 to 6.2.2

Lucinda Evans, Coordinator, Corporate Office Present for items 1 to 4.1.3

Rosalee Mason, Coordinator, Corporate Office Present for items 1 to 4.1.3, 5 to 5.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Ismahan Abdullah, Administrator, TA Present for items 1 to 4.2.2

Celia Mayers, Administrator, TA Present for items 5 to 5.2.2

Evidence review group representatives present

Maiwenn Al, Kleijnen Systematic Reviews Ltd Present for items 1 to 4.1.3

Rob Riemsma, Kleijnen Systematic Reviews Ltd Present for items 1 to 4.1.3

Pim Wetzelaer, Kleijnen Systematic Reviews Ltd Present for items 1 to 4.1.3

Nigel Armstrong, Kleijnen Systematic Reviews Ltd Present for items 5 to 5.1.3

Bram Ramaekers, Kleijnen Systematic Reviews Ltd Present for items 5 to 5.1.3

Dwayne Boyers, Aberdeen HTA Group Present for items 6 to 6.1.3

David Cooper, Aberdeen HTA Group Present for items 6 to 6.1.3

Clinical and patient experts present

Professor Peter Clark, National Clinical Lead for cancer drugs, NHS England , Present for all items

Dr Kate Garcez, Consultant Clinical Oncologist, Clinical expert nominated by the Royal College of Physicians (RCP), Present for items 1 to 4.1.3

Dr Robert Murray, Consultant Endocrinologist, Clinical expert nominated by the Society for Endocrinology, Present for items 1 to 4.1.3

Dr Kirstie Purnell, Patient expert nominated by Association for Multiple Endocrine Neoplasia Disorders (AMEND), Present for items 1 to 4.1.3

xxxxxxxxxxxxxx, Patient expert nominated by the Association for Multiple Endocrine Neoplasia Disorders (AMEND), Present for items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 12 May 2021.

### Appraisal of selpercatinib for treating advanced thyroid cancer with RET alterations (ID3744)

* 1. Part 1 – Open session
		1. The Chair Professor Gary McVeigh welcomed the invited clinical and patient experts, the national clinical lead for cancer drugs, external review group representatives, members of the public, and company representatives from Eli Lilly.
		2. The chair asked all committee members, clinical and patient experts, the national clinical lead for cancer drugs, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Bernard Khoo, Professor Sofia Dias and Rebecca Harmston.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Appraisal of nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy - CDF Review of TA490 (ID1585)

* 1. Part 1 – Open session
		1. The Chair Dr Lindsay Smith welcomed, the national clinical lead for cancer drugs, external review group representatives, members of the public and company representatives from Bristol-Myers Squibb.
		2. The chair asked all committee members, the national clinical lead for cancer drugs, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
	+ 1. The Chair led a discussion of the evidence presented to the committee.
	1. Part 2 – Closed session (company representatives, external group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (ID3735)

* 1. Part 1 – Open session
		1. The Chair Dr Lindsay Smith welcomed the national clinical lead for cancer drugs, external review group representatives, members of the public and company representatives on behalf of Merck Serono & Pfizer.
		2. The chair asked all committee members, the national clinical lead for cancer drugs, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, external review group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 14 July 2021 and will start promptly at 9:30am.